GOVERNMENT OF THE DISTRICT OF COLUMBIA
Office of the Attorney General

2017 DEC 11 PM 4:30

OFFICE OF THE SECRETARY

ATTORNEY GENERAL
KARL A. RACINE

December 11, 2017

The Honorable Phil Mendelson
Chairman, Council of the District of Columbia
John A. Wilson Building
1350 Pennsylvania Avenue, N.W.
Suite 504
Washington, DC 20004

Dear Chairman Mendelson:

I am writing to transmit the "Revised Synthetics Abatement and Full Enforcement Drug Control Amendment Act of 2017"; "Revised Synthetics Abatement and Full Enforcement Drug Control Emergency Declaration Resolution of 2017"; "Revised Synthetics Abatement and Full Enforcement Drug Control Emergency Amendment Act of 2017"; and the "Revised Synthetics Abatement and Full Enforcement Drug Control Temporary Amendment Act of 2017" for introduction and consideration by the Council of the District of Columbia. Much like the previous emergency version of this legislation, this version criminalizes synthetic cannabinoids and synthetic cathinones (commonly known as synthetic drugs) based on the class of the chemical compound, not the individual compound. However, this version takes the vitally important step of including variants of fentanyl. Jurisdictions around the country are facing upticks in deaths related to fentanyl, which is most commonly associated with opioid abuse. Classifying new substances based on the class of the compound solves three problems that law enforcement across the nation has been grappling with:

1. It minimizes the necessity of enumerating specific synthetic drug compounds on Schedule I of the District of Columbia's Controlled Substances List;
2. It makes laboratory testing for fentanyl, synthetic cannabinoids and synthetic cathinones more efficient; and,
3. Law enforcement will no longer need to rely on an impractical controlled substances analogue statute to prosecute emerging synthetic drugs.

This legislation derives from the Office of the Attorney General's(OAG) Emerging Drug Trends Task Force's collaboration with the Department of Forensic Science and other local and federal government partners. By combining information and enforcement tactics from multiple

jurisdictions across the country, the proposed legislation is at the forefront of synthetic drug testing statutes in the nation. Additionally, the legislation codifies certain current District regulations regarding synthetic cannabinoid and cathinone regulations. It is important to note that OAG views individual drug use as a health issue and it should be treated as such. The purpose of this legislation is to combat the sources of this urgent and deadly problem. OAG will work with stakeholders to ensure the public and legislative record reflects that goal.

If you have any questions, your staff may contact my Legislative Director, James A. Pittman, on (202) 724-6517.

Sincerely,

Karl A. Racine
Attorney General for the District of Columbia

Chairman Phil Mendelson at
the request of the Attorney General

A BILL

IN THE COUNCIL OF THE DISTRICT OF COLUMBIA

To amend, on a temporary basis, the District of Columbia Uniform Controlled Substances Act of 1981 to add certain classes and substances to the list of Schedule I controlled substances.

BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this Act may be cited as the "Revised Synthetics Abatement and Full Enforcement Drug Control Temporary Amendment Act of 2017".

Sec. 2. The District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-901.01 *et seq.*), is amended as follows:

(a) Section 102 (27) (D.C. Official Code § 48-901.02(27)) is amended as follows

(1) Strike the phrase "as used in section 204(3) and section 206(1)(D)" and insert the phrase "as used in section 204(3), (5), and (6) and section 206(1)(D)" in its place.

(2) Strike the phrase "As used in section 204(3)" and insert the phrase "As used in section 204(3), (5), and (6)" in its place.

(b) Section 204 (D.C. Official Code § 48-902.04) is amended as follows:

(1) Paragraph (3) is amended as follows:

(A) The lead-in language is amended by striking the phrase "(for purposes of this paragraph only, the term "isomer" includes the optical, position, and geometric isomers)".

(B) New subparagraphs (G-i) through (G-xxii) are added to read as follows:

"(G-i) 25I-NBOMe (also known as 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);

"(G-ii) 25B-NBOMe (also known as 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);

"(G-iii) 25C-NBOMe (also known as 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine);

"(G-iv) 5-APB (also known as 1-(benzofuran-5-yl)propan-2-amine);

"(G-v) 5-APDB (also known as 1-(2,3-dihydrobenzofuran-5-yl)propan-2-amine);

"(G-vi) 6-APB (also known as 1-(1-benzofuran-6-yl)propan-2-amine);

"(G-vii) 6-APDB (also known as1-(2,3-dihydrobenzofuran-6-yl)propan-2-amine);

"(G-viii) 3-methoxy-PCE (also known as *N*-ethyl-1-(3-methoxyphenyl)cyclohexanamine);

"(G-ix) 3-methoxy-PCP (also known as 1-[1-(3-methoxyphenyl)cyclohexyl]piperidine);

"(G-x) 4-methoxy-PCP (also known as 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine);

"(G-xi) 5-MeO-DALT (also known as *N,N*-diallyl-5-methoxytryptamine);

"(G-xii) 4-AcO-DMT (also known as 5-acetoxy-*N*,*N*-dimethyltryptamine);".

(C) A new subparagraph (M-i) is added to read as follows:

"(M-i) Methoxetamine (also known as 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone);".

(D) Subparagraph (JJ) is amended by striking the word "and".

(E) Subparagraph (KK) is amended by striking the phrase "(2C-P);" and inserting the phrase "(2C-P); and" in its place.

(F) A new subparagraph (LL) is added to read as follows:

"(LL) Cathinone;".

(2) Paragraph (5) is amended to read as follows:

"(5) As used in this paragraph, the term "synthetic cathinones" includes any material, compound, mixture, or preparation that is not otherwise listed as a controlled substance in this schedule or in Schedules II through V, is not approved by the Food and Drug Administration as a drug, and is structurally derived from or contains any quantity of the following substances, their salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues, unless specifically excepted, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:

"(A) Classified Synthetic Cathinones:

"(i) Cathinones. Any compound, other than methylnenedioxy cathinones and pyrrolidine cathinones, containing a 2-amino-1-propanone structure with substitution at the 1-position with a monocyclic ring system, with or without alkyl, alkoxyl, or

halo substitutions, and a substitution at the nitrogen atom by an alkyl group, cycloalkyl group, or incorporation into a heterocyclic structure. Examples of this structural class include:

"(I) Mephedrone, also known as:

"(aa) 2-(methylamino)-1-(4-methylphenyl)-1-propanone;

"(bb) 4-MeMC;

"(cc) 4-Methylmethcathinone;

"(dd) 4-Methylephedrone; or

"(ee) 4-MMC;

"(II) Dimethylcathinone, also known as:

"(aa) 2-(dimethylamino)-1-phenyl-1-propanone; or

"(bb) N,N-Dimethylcathinone;

"(III) Ethcathinone, also known as:

"(aa) 2-(ethylamino)-1-phenyl-1-propanone;

"(bb) Ethylcathinone;

"(cc) N-Ethylcathinone; or

"(dd) 2-Ethylaminobuphedro;

"(IV) Buphedrone, also known as:

"(aa) 2-(methylamino)-1-phenylbutan-1-one; or

"(bb) MABP;

"(V) 3,4-DMMC, also known as:

"(aa) 1-(3,4-dimethylphenyl)-2-(methylamino)-1-propanone; or

"(bb) 3,4-Dimethylmethcathinone;

"(VI) EMC, also known as:

"(aa) 1-(4-ethylphenyl)-2-(methylamino)propan-1-one;

"(bb) 4-EMC; or

"(cc) 4-Ethylmethcathinone;

"(VII) Fluoromethcathinone (also known as 1-(4-fluorophenyl)-2-(methylamino) propan-1-one);

"(VIII) 3-FMC (also known as 3-fluoro-N-methylcathinone);

"(IX) 4-FMC, also known as:

"(aa) 1-(4-fluorophenyl)-2-(methylamino)propan-1-one;

"(bb) 4-fluoro-N-methylcathinone; or

"(cc) Flephedrone;

"(X) 4-MeBP, also known as:

"(aa) 2-(methylamino)-1-(4-methylphenyl)-1-butanone;

"(bb) 4-Methylbuphedrone;

"(cc) 4-methyl BP; or

"(dd) 4-MeMABP

"(XI) 3-MEC, also known as:

"(aa) 2-(ethylamino)-1-(m-tolyl)propan-1-one; or

"(bb) 3-Methyl-N-ethylcathinone;

"(XII) 4-MEC, also known as:

"(aa) 2-(ethylamino)-1-(4-methylphenyl)-1-propanone; or

"(bb) 4-Methyl-N-ethylcathinone;

"(XIII) 3-MMC, also known as:

"(aa) 2-(methylamino)-1-(3-methylphenyl)-1-propanone;

"(bb) 3-methyl MS; or

"(cc) 3-Methylmethcathinone;

"(XIV) Methedrone (also known as 1-(4-methoxyphenyl)-2-(methylamino)-1-propanone); or

"(XV) Pentedrone (also known as 2-(methylamino)-1-phenylpentan-1-one);

"(ii) Methylenedioxy Cathinones. Any compound containing a 2-amino-1-propanone structure with substitution at the 1-position with a monocyclic or fused polycyclic ring system and a substitution at any position of the ring system with an alkyl, haloalkyl, halogen, alkylenedioxy, or alkoxy group, whether or not further substituted at any position on the ring system to any extent. Examples of this structural class include:

"(I) 3-fluoromethylone;

"(II) Methylone, also known as

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)-1-propanone; or

"(bb) 3,4-Methylenedioxy-N-methylcathinone);

"(III) N-ethyl Pentylone, also known as:

"(aa) Ephylone; or

"(bb) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone;

"(IV) bk-MDDMA, also known as:

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one;

"(bb) Dimethylone;

"(cc) *N,N*-dimethyl-3′,4′-methylenedioxycathinone;

"(dd) *N,N*-dimethyl-3,4-methylenedioxycathinone; or

"(ee) N,N-Dimethyl MDCATH;

"(V) Butylone, also known as 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one);

"(VI) Ethylone, also known as:

"(aa) 3,4-Methylenedioxy-N-ethylcathinone; or

"(bb) MDEC; or

"(VII) Pentylone (also known as 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one);

"(iii) Pyrrolidine Cathinones. Any compound containing a 2-amino-1-propanone structure with substitution at the 1-position with a alkyl, cyclic or fused polycyclic ring system and a substitution at the 3-position carbon with an alkyl, haloalkyl,

halogen, alkoxy or alkylenedioxy group, and a substitution at the nitrogen atom incorporation into a heterocyclic structure, with or without further halogen substitutions. Examples include:

"(I) α-PVP (also known as α-pyrrolidinopentiophenone);

"(II) α-pyrrolidinopropiophenone, also known as:

"(aa) 1-phenyl-2-(1-pyrrolidinyl)-1-propanone; or

"(bb) α-PPP;

"(III) α-PBP, also known as:

"(aa) 1-phenyl-2-(1-pyrrolidinyl)-1-butanone; or

"(bb) α-pyrrolidinobutiophenone;

"(IV) MDPBP, also known as:

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-butanone; or

"(bb) 3,4-Methylenedioxy-α-Pyrrolidinobutiophenone;

"(V) MDPPP, also known as:

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-propanone; or

"(bb) 3,4-Methylenedioxy-α-Pyrrolidinopropiophenone;

"(VI) MDPV, also known as:

"(aa) 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone; or

"(bb) 3,4-Methylenedioxy Pyrovalerone;

"(VII) 4-MePPP, also known as

"(aa) 4'-methyl-α-Pyrrolidinopropiophenone;

"(bb) 4'-methyl PPP; or

"(cc) 2-(pyrrolidin-1-yl)-1-(p-tolyl)propan-1-one;

"(VIII) 4'-methyl PHP, also known as:

"(aa) 4'-methyl-α-pyrrolidinohexanophenone;

"(bb) MPHP;

"(cc) 4'-methyl- α-PHP; or

"(dd) PV4;

"(IX) Naphyrone, also known as:

"(aa) (RS)-1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one; or

"(bb) Naphpyrovalerone;

"(X) C-PVP, also known as:

"(aa) 4-Chloro-α-PVP; or

"(bb) 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one";

"(iv) Piperazine Stimulants. Any compound containing or structurally derived from a piperazine, or diethylenediamine, structure with or without substitution at one of the nitrogen atoms of the piperazine ring to any extent, including alkyl, cycloalkyl, or fused ring systems, with or without further halogen substitutions. Examples include:

"(I) BZP, also known as:

"(aa) 1-(phenylmethyl)-piperazine;

"(bb) 1-Benzylpiperazine; or

"(cc) N-Benzylpiperazine; and

"(II) TMFPP, also known as:

"(aa) 1-[3-(trifluoromethyl)phenyl]-piperazine;

"(bb) 1-(m-Trifluoromethylphenyl) piperazine; or

"(cc) 3-Trifluoromethylphenylpiperazine.

"(B) Unclassified Synthetic Cathinones:

"(i) Aminorex (also known as (RS)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine);

"(ii) α-ET, also known as:

"(I) α-ethyl-1H-indole-3-ethanamine;

"(II) α-ethyltryptamine; or

"(III) 3-Indolybutylamine;

"(iii) α-MT, also known as:

"(I) α-methyl-1H-indole-3-ethanamine; or

"(II) α-methyltryptamine;

"(iv) EMA, also known as:

"(I) N-ethyl-α-methyl-benzeneethanamine; or

"(II) N-Ethylamphetamine;

"(v) Fenethylline (also known as (RS)-1,3-dimethyl- 7-[2-(1-bpphenylpropan-2-ylamino)ethyl]purine-2,6-dione);

"(vi) N-hydroxy MDA, also known as:

"(I) MDOH;

"(I) N-hydroxy-α-methyl-1,3-benzodioxole-5-ethanamine;

or

"(II) N-Hydroxy-3,4-methylenedioxyamphetamine;

"(vii) N,N-DMA, also known as:

"(I) N,N,α-trimethyl-benzeethanamine;

"(II) N,N-Dimethylamphetamine;

"(III) Dimetamfetamine; or

"(III) Metrotonin.".

(3) A new paragraph (6) is added to read as follows:

"(6) Synthetic cannabimimetic agents (also known as "synthetic cannabinoids"), which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:

"(A) Classified Synthetic Cannabimimetic Agents:

"(i) Adamantanoylindoles: Any compound containing or structurally derived from an adamantanyl-(1H-indol-3-yl)methanone structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl,

(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent. Examples include:

"(I) AB-001, also known as:

"(aa) (1s,3s)-adamantan-1-yl(1-pentyl-1H-indol-3-yl)methanone; or

"(bb) JWH 018 adamantyl analog; and

"(II) AM-1248, also known as:

"(aa) [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]tricyclo[3.3.1.13,7]dec-1-yl-methanone; or

"(bb) AM1248;

"(ii) Benzimidazole Ketone: Any compound containing or structurally derived from (benzimidazole-2-yl) methanone structure with or without substitution at either nitrogen atom of the benzimidazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Benzimidazole Ketones include:

"(I) FUBIMINA, also known as:

"(aa) (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone; or

"(bb) AM2201 benzimidazole analog; and

"(II) JWH-018 benzimidazole analog, also known as:

"(aa) naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-yl)methanone; or

"(bb) BIM-018;

"(iii) Benzoylindoles: Any compound containing or structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent. Examples include:

"(I) AM-630, also known as:

"(aa) [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)-methanone;

"(bb) AM630; or

"(cc) Iodopravadoline ;

"(II) AM-661 (also known as 1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole);

"(III) AM-679, also known as:

"(aa) (2-iodophenyl)(1-pentyl-1H-indol-3

yl)methanone; or

"(bb) AM679;

"(IV) AM-694, also known as:

"(aa) [1-(5-fluoropentyl)-1H-indol-3-yl](2-iodophenyl)-methanone;

"(bb) 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; or

"(cc) AM694;

"(V) AM-1241, also known as:

"(aa) (2-iodo-5-nitrophenyl)-(1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl)methanone; or

"(bb) AM1241;

"(VI) AM-2233, also known as:

"(aa) (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-methanone; or

"(bb) AM2233;

"(VII) RCS-4, also known as:

"(aa) (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone; or

"(bb) SR-19; and

"(VIII) WIN 48,098, also known as

"(aa) (4-methoxyphenyl)[2-methyl]-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-methanone; or

"(bb) "Pravadoline";

"(iv) Carbazole Ketone: Any compound containing or structurally derived from (9H-carbazole-3-yl) methanone structure with or without substitution at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted at the carbazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples include EG-018 (also known as naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone);

"(v) Indazole Amide: Any compound containing or structurally derived from 3-carboxamide-1H-indazoles, whether or not substituted in the indazole ring to any extent and substituted to any degree on the carboxamide nitrogen and 3-carboxamide-1H-indoles, whether or not substituted in the indole ring to any extent and substituted to any degree on the carboxamide nitrogen. Examples include:

"(I) AB-CHMINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

"(II) AB-FUBINACA (also known as N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide);

"(III) AB-PINACA (also known as N-(1-amino-3-methyl-

1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide);

"(IV) 5F AB-PINACA, also known as:

"(aa) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or

"(bb) 5-fluoro AB-PINACA;

"(V) ADB-FUBINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1-H-indazole-3-carboxamide);

"(VI) ADB-PINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide);

"(VII) 5F ADB-PINACA, also known as:

"(aa) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide); or

"(bb) 5-fluoro ADB-PINACA;

"(VIII) FUB-AMB, also known as:

"(aa) methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate;

"(bb) AMB-FUBINACA; or

"(cc) MMB-FUBINACA;

"(IX) 5-fluoro-AMB (also known as (S)- methyl 2- (1- (5-fluoropentyl)- 1H- indazole- 3-carboxamido)- 3- methylbutanoate);

"(X) MAB-CHMINACA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide);

"(XI) MMB CHMINACA, also known as:

"(aa) methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate; or

"(bb) MDMB-CHMICA;

"(XII) 5F MN-18, also known as:

"(aa) 1-(5-fluoropentyl)-N-1-naphthalenyl-1H-indazole-3-carboxamide; or

"(bb) 5-fluoro MN-18;

"(XIII) 5F-APINACA, also known as:

"(aa) 5-fluoro-APINACA

"(bb) 5F-AKB-48;

"(cc) 5F-AKB48;

"(dd) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide; or

"(ee) *N*-(1-adamantyl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide); and

"(XIV) APINACA, also known as:

"(aa) AKB-48;

"(bb) AKB48;

"(cc) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide; or

"(dd) *N*-(1-adamantyl)-1-pentyl-1*H*-indazole-3-carboxamide;

"(vi) Cyclohexylphenols: Any compound containing or structurally

393 derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic
394 ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-
395 (N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl,
396 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not
397 further substituted in the cyclohexyl ring to any extent. Examples include:
398 "(I) CP 47,497 (also known as 2-[(1S,3R)-3-
399 hydroxycyclohexyl]- 5-(2-methyloctan-2-yl)phenol);
400 "(II) CP 47,497 C8 homologue, also known as:
401 "(aa) rel-2-[(1S,3R)-3-hydroxycyclohexyl]-5-(2-
402 methylnonan-2-yl)phenol; or
403 "(bb) Cannabicyclohexanol;
404 "(III) CP 55,490;
405 "(IV) CP 55,940 (also known as 5-(1,1-dimethylheptyl)-2-
406 [(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol); and
407 "(V) CP 56,667;
408 "(vii) Cyclopropanoylindoles: Any compound containing or
409 structurally derived from 3-(cyclopropylmethanoyl)indole, 3-(cyclopropylmethanone)indole, 3-
410 (cyclobutylmethanone)indole or 3-(cyclopentylmethanone)indole by substitution at the nitrogen
411 atom of the indole ring, whether or not further substituted in the indole ring to any extent, and
412 whether or not substituted on the cyclopropyl, cyclobutyl, or cyclopentyl rings to any extent.
413 Cyclopropanoylindoles include cyclopropylmethanone indoles, as well as other
414 cycloalkanemethanones, whether or not substituted at the nitrogen atom on the indole ring,

whether or not further substituted in the indole ring to any extent, and whether or not substituted on the cycloalkane ring to any extent. Examples of this structural class include:

"(I) A-796,260, also known as:

"(aa) [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or

"(bb) A-796260;

"(II) A-834,735, also known as:

"(aa) [1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or

"(bb) A-834735;

"(III) AB-034 (also known as [1-[(N-methylpiperidin-2-yl)methyl]-1H-indole-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone);

"(IV) UR-144 (also known as 1-pentyl-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole);

"(V) 5-bromo-UR-144, also known as:

"(aa) [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone; or

"(bb) UR-144 N-(5-bromopentyl) analog;

"(VI) 5-chloro-UR-144, also known as:

"(aa) 1-(5-chloropentyl)-3-(2, 2, 3, 3-tetramethylcyclopropoyl)indole; or

"(bb) 5Cl-UR-144;

"(VII) XLR11, also known as:

"(aa) 1-(5-fluoropentyl)-3-(2,2,3, 3-tetramethylcyclopropoyl)indole;

"(bb) 5-FUR-144; or

"(cc) 5-fluoro UR-144; and

"(VIII) FUB-144 (also known as [1-(4-Fluorobenzyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone);

"(viii) Hexahydrodibenzopyrans: Any compound containing or structurally derived from Hexahydrodibenzopyrans, whether or not substituted in the tricyclic ring system, except where contained in cannabis or cannabis resin;

"(ix) Indazole Ester (also known as Carboxylate indazole): Any compound containing or structurally derived from 3-carboxylate-indazoles, whether or not substituted in the indazole ring to any extent or substituted to any degree on the carboxylate, whether or not substituted to any extent in the indazole ring or on the carboxylate oxygen. Examples of indazole esters include 5-fluoro SDB-005, also known as:

"(I) naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate; or

"(II) 5F SDB-005;

"(x) Indole Amides: Any compound containing or structurally derived from or containing a 1H-Indole-3-carboxamide structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not

substituted at the carboxamide group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. Indole amides include:

"(I) Adamantylamidoindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide structure, whether or not further substituted in the indole ring to any extent and whether or not substituted in the adamantyl ring to any extent;

"(II) Adamantylindoles, or any compound containing or structurally derived from an N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, and whether or not substituted on the adamantyl ring to any extent;

"(III) 5F ABICA, also known as:

"(aa) (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide;

"(bb) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide; or

"(cc) 5-fluoro ABICA;

"(IV) ADBICA (also known as N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide));

"(V) 5F-ADBICA, also known as:

"(aa) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-

(5-fluoropentyl)-1H-indole-3-carboxamide; or

"(bb) 5-fluoro-ADBICA;

"(VI) NNE1 (also known as N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide);

"(VII) 5F-NNE1, also known as:

"(aa) 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide); or

"(bb) 5-fluoro-NNE1

"(VIII) SDB-006 (also known as N-benzyl-1-pentyl-1H-indole-3-carboxamide);

"(IX) 5F-SDB-006, also known as:

"(aa) N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide); or

"(bb) 5-fluoro-SDB-006;

"(X) 2NE1, also known as:

"(aa) APICA;

"(bb) JWH 018 adamantyl carboxamide; or

"(cc) 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide;

"(XI) STS-135, also known as:

"(aa) 1-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide;

"(bb) N-adamantyl-1-fluoropentylindole-3-

Carboxamide;

"(cc) 5F-APICA; or

"(dd) 5-fluoro-APICA;

"(XII) SDB-006 (also known as N-benzyl-1-pentyl-1H-indole-3-carboxamide); and

"(XIII) STS-135, also known as:

"(aa) 1-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide;

"(bb) N-adamantyl-1-fluoropentylindole-3-Carboxamide;

"(cc) 5F-APICA; or

"(dd) 5-fluoro-APICA;

"(xi) Indole Esters: Any compound containing or structurally derived from a 1H-Indole-3-carboxylate structure with or without substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, whether or not substituted at the carboxylate group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group and whether or not further substituted in the indole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl

rings to any extent. Indole Esters may also be referred to as Quinolinylindolecarboxylates. Indole esters include:

"(I) Quinolinyl ester indoles, or any compound containing or structurally derived from Quinolinyl ester indoles, being any compound containing or structurally derived from 1H-indole-3carboxylic acid-8-quinolinyl ester, whether or not substituted in the indole ring to any extent or the quinolone ring to any extent;

"(II) BB-22, also known as:

"(aa) 1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;

"(bb) quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate; or

"(cc) QUCHIC;

"(III) FDU-PB-22 (also known as naphthalen-1-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate);

"(IV) FUB-PB-22, also known as:

"(aa) 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylic acid, 8-quinolinyl ester; or

"(bb) Quinolin-8-yl 1-(4-fluorobenzyl)-1*H*-indole-3-carboxylate;

"(V) NM2201, also known as:

"(aa) naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; or

"(bb) CBL-2201;

"(VI) PB-22, also known as:

"(aa) 1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid;

"(bb) quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate;

"(cc) 8-Quinolinyl 1-pentyl-1H-indole-3-carboxylate; or

"(dd) "QUPIC"; and

"(VII) 5F-PB-22, also known as:

"(aa) 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid;

"(bb) quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;

"(cc) 8-Quinolinyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;

"(dd) 5-fluoro-PB-22; or

"(ee) 5-fluoro QUPIC;

"(xii) Naphthoylindoles: Any compound containing or structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl group, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the naphthyl ring to

any extent, including the following: AM-678, AM-1220, AM-1221, AM-1235, AM-2232, EAM-2201, JWH-004, JWH-007, JWH-009, JWH-011, JWH-015, JWH-016, JWH-018, JWH-019, JWH-020, JWH-022, JWH-046, JWH-047, JWH-048, JWH-049, JWH-050, JWH-070, JWH-071, JWH-072, JWH-073, JWH-076, JWH-079, JWH-080, JWH-081, JWH-082, JWH-094, JWH-096, JWH-098, JWH-116, JWH-120, JWH-122, JWH-148, JWH-149, JWH-164, JWH-166, JWH-180, JWH-181, JWH-182, JWH-189, JWH-193, JWH-198, JWH-200, JWH-210, JWH-211, JWH-212, JWH-213, JWH-234, JWH-235, JWH-236, JWH-239, JWH-240, JWH-241, JWH-242, JWH-258, JWH-262, JWH-386, JWH-387, JWH-394, JWH-395, JWH-397, JWH-398, JWH-399, JWH-400, JWH-412, JWH-413, JWH-414, JWH-415, JWH-424, MAM-2201, WIN 55-212. Napthoylindoles also include:

"(I) AM-2201 (also known as (1-(5-fluoropentyl)-3-(1-naphthoyl)indole); and

"(II) WIN 55,212-2, also known as:

"(aa) (R)-(+)-[2,3-dihydro-5-methyl-3- (4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone; or

"(bb) [2,3-Dihydro-5-methyl- 3-(4-morpholinylmethyl)pyrrolo[(1,2,3-de)-1,4-benzoxazin-6-yl]-1-napthalenylmethanone);

"(xiii) Naphthoylnaphthalenes: Any compound containing or structurally derived from naphthalene-1-yl-(naphthalene-1-yl) methanone with substitutions on either of the naphthalene rings to any extent. Naphthoylnaphthalenes include CB-13, also known as CRA-13 or1-naphthalenyl[4-(pentylox)-1-naphthalenyl]-methanone;

CRA-13;

"(xiv) Naphthoylpyrroles: Any compound containing or

structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including the following: JWH-030, JWH-031, JWH-145, JWH-146, JWH-147, JWH-150, JWH-156, JWH-243, JWH-244, JWH-245, JWH-246, JWH-292, JWH-293, JWH-307, JWH-308, JWH-309, JWH-346, JWH-348, JWH-363, JWH-364, JWH-365, JWH-367, JWH-368, JWH-369, JWH-370, JWH-371, JWH-373, JWH-392;

"(xv) Naphthylamidoindoles: Any compound containing or structurally derived from a N-(naphthyl)-indole-3-carboxamide structure, whether or not further substituted to any extent in the indole ring or the naphthyl ring;

"(xvi) Naphthylmethyl Indoles: Any compound containing or structurally derived from 1H-indol-3-yl-(1-naphthyl)methane structure, also known as napthylmethylindoles, with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted on the indole ring to any extent and whether or not substituted on the naphthyl ring to any extent. Examples of this structural class include:

"(I) JWH-175 (also known as 3-(1-naphthalenylmethyl)-1-pentyl-1H-indole);

"(II) JWH-184 (also known as 3-[(4-methyl-1-

naphthalenyl)methyl]-1-pentyl-1H-indole);

"(III) JWH-185 (also known as 3-[(4-methoxy-1-naphthalenyl)methyl]-1-pentyl-1H-indole);

"(IV) JWH-192 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methylnaphthalen-1-ylmethane);

"(V) JWH-194 (also known as 2-methyl-1-pentyl-1H-indol-3-yl-(4-methyl-1-naphthyl)methane);

"(VI) JWH-195 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-1-ylmethane);

"(VII) JWH-196 (also known as 2-methyl-3-(1-naphthalenylmethyl)-1-pentyl-1H-Indole);

"(XVIII) JWH-197 (also known as 2-methyl-1-pentyl-1H-indol-3-yl-(4-methoxy-1-naphthyl)methane); and

"(XIV) JWH-199 (also known as (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-ylmethane);

"(xvii) Naphthylmethylindenes: Any compound containing or structurally derived from a naphthylideneindene structure or that is structurally derived from 1-(1-naphthylmethyl)indene with substitution at the 3-position of the indene ring by alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent. Examples include:

"(I) JWH-171;

"(II) JWH-176 (also known as 1-[(E)-(3-pentyl-1H-inden-1-ylidene)methyl]-naphthalene); and

"(III) JWH-220;

"(xviii) Phenylacetylindoles: Any compound containing or structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, or 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or (tetrahydropyran-4-yl)methyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including: JWH-167, JWH-201, JWH-202, JWH-203, JWH-204, JWH-205, JWH-206, JWH-207, JWH-208, JWH-209, JWH-237, JWH-248, JWH-249, JWH-250, JWH-251, JWH-253, JWH-302, JWH-303, JWH-304, JWH-305, JWH-306, JWH-311, JWH-312, JWH-313, JWH-314, JWH-315, JWH-316, RCS-8, SR-18, and Cannabipiperidiethanone (also known as 2-(2-methoxyphenyl)-1-[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-ethanone);

"(xix) Quinolinoyl pyrazole: Any compound containing or structurally derived from Quinolinoyl pyrazole carboxylate (also known as Quinolinyl fluoropentyl fluorophenyl pyrazole carboxylate);

"(xx) Tetrahydrobenzochromen: Any compound containing or structurally derived from (6aR,10aR)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol. Includes tetrahydrodibenzopyrans, or any compound containing or structurally derived from tetrahydrodibenzopyrans, whether or not

667 substituted in the tricyclic ring system, but does not include tetrahydrodibenzopyrans that are
668 contained in cannabis or cannabis resin. Examples of this structural class include:
669 "(I) AM-087 (also known as (6aR,10aR)-3-(2-methyl-6-
670 bromohex-2-yl)- 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
671 "(II) AM-411 (also known as (6aR,10aR)-3-(1-adamantyl)-
672 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
673 "(III) HU-210, also known as:
674 "(aa) 3-(1,1'-dimethylheptyl)-6aR,7,10,10aR-
675 tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;
676 "(bb) [(6aR,10aR)-9-(hydroxymethyl)-6,6-
677 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- tetrahydrobenzo[c]chromen-1-ol;
678 "(cc) 1,1-Dimethylheptyl-11-
679 hydroxytetrahydrocannabinol; or
680 "(dd) 1,1-dimethylheptyl-11-hydroxy-delta8-
681 tetrahydrocannabinol;
682 "(IV) HU-211, also known as:
683 "(aa) 3-(1,1-dimethylheptyl)-6aS,7,10,10aS-
684 tetrahydro-1-hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-methanol;
685 "(bb) (6aS,10aS)-9-(hydroxymethyl)-6,6-
686 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
687 "(cc) (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-
688 3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; or
689 "(dd) "Dexanabinol";

"(V) HU-243, also known as

"(aa) (6aR,8S,9S,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-tetrahydro-6aH-benzo[c]chromen-1-ol; or

"(bb) 3-dimethylheptyl-11-hydroxyhexahydrocannabinol;

"(VI) JWH-051 (also known as (6aR,10aR)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-9-yl)methanol);

"(VII) JWH-133 (also known as (6aR,10aR)-3-(1,1-Dimethylbutyl) -6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran); and

"(VIII) JWH-359 (also known as (6aR,10aR)- 1-methoxy-6,6,9-trimethyl- 3-[(2R)-1,1,2-trimethylbutyl]- 6a,7,10,10a-tetrahydrobenzo[c]chromene);

"(xxi) Δ8-Tetrahydrocannabinol: Any compound containing or structurally derived from 11-hydroxy-Δ8-tetrahydrocannabinol structure, also known as dibenzopyrans, with further substitution on the 3-pentyl group by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkyethyl, 1-(n-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group;

"(xxii) Tetramethylcyclopropane-thiazole carboxamides: Any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol-2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring by alkyl, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, alkoxy, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)alkyl, (4-tetrahydropyran)alkyl, or 2-

(4-morpholinyl)alkyl, whether or not further substituted in the thiazole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent, including the group Tetramethylcyclopropyl thiazoles, or any compound containing or structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- 2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen atom of the thiazole ring, whether or not further substituted in the thiazole ring to any extent, whether or not substituted in the tetramethylcyclopropyl ring to any extent. Tetramethylcyclopropane-thiazole carboxamides also include A-836,339, also known as:

"(I) [N(Z)]-N-[3-(2-methoxyethyl)-4,5-dimethyl-2(3H)-thiazolylidene]-2,2,3,3-tetramethyl-cyclopropanecarboxamide;

"(II) N-[3-(2-Methoxyethyl)-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-2,2,3,3-tetramethylcyclopropanecarboxamide: or

"(III) A-836339;

"(xxiii) Benzodihydropyrans: Any compound containing or structurally derived from benzodihydropyrans, by substitution on the benzyl ring by hydroxy, alkyl, haloalkyl, alkoxy, cycloalkyl, alkene, haloalkene, cycloalkane, or by substitution on the pyran ring by alkyl, cycloalkyl, cycloalkene, or cycloalkoxy group to any extent. Examples of this structural class include:

"(I) AM-855 (also known as (4aR,12bR)-8-hexyl-2,5,5-trimethyl-1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol);

"(II) AM-905 (also known as (6aR,9R,10aR)-3-[(E)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol);

"(III) AM-906 (also known as (6aR,9R,10aR)-3-[(Z)-hept-1-enyl]-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-1-ol);

"(IV) AM-2389 (also known as (6aR,9R,10aR)-3-(1-hexylcyclobut-1-yl)-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9 diol); and

"(V) JWH-057 (also known as (6aR,10aR)-3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-Dibenzo[b,d]pyran);

"(xxiv) Benzimidazole Ketone: Any compound containing or structurally derived from [1H-indazol-3-yl](1-naphthyl)methanone structure with or without substitution at either nitrogen atom of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or halophenyl group, with substitution at the carbon of the methanone group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, 1-amino-3, 3-dimethyl-1-oxobutan-2-yl, 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-methoxy-3, 3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether or not further substituted in the benzimidazole, adamantyl, naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. Examples of this structural class include:

"(I) THJ-2201 (also known as [1-(5-Fluoropentyl)-1H-indazol-3-yl](1-naphthyl)methanone); and

"(II) THJ-018 (also known as 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone);

"(B) Unclassified Synthetic Cannabimimetic Agents:

"(i) AM-356, also known as:

"(I) AM356;

"(II) arachidonyl-1'-hydroxy-2'-propylamide;

"(III) N-(2-hydroxy-1R-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide;

"(IV) (R)-(+)-Arachidonyl-1'-Hydroxy-2'-Propylamide;

"(V) Methanandamide; or

"(VI) R-1 Methanandamide;

"(ii) BAY38-7271 (also known as (-)-(R)-3-(2-Hydroxymethylindanyl -4-oxy) phenyl-4,4,4-trifluorobutyl-1-sulfonate);

"(iii) CP 50,556-1, also known as:

"(I) 9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]acetate;

"(II) [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-; octahydrophenanthridin-1-yl] acetate;

"(III) [9-hydroxy-6-methyl-3-[5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10, 10a-octahydrophenanthridin-1-yl]acetate; or

"(IV) "Levonantradol";

"(iv) HU-308 (also known as (91R,2R,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol);

"(v) HU-331 (also known as 3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-dione);

"(vi) JTE-907 (also known as N-(benzol[1,3]dioxol-5-ylmethyl) – 7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide);

"(vii) Mepirapim (also known as (4-methylpiperazin-1-yl)(1-pentyl-1H-indol-3-yl) Methanone);

"(viii) URB597 (also known as [3-(3-carbamoylphenyl)phenyl] – N-Cyclohexylcarbamate);

"(ix) URB602, also known as:

"(I) [1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester; or

"(II) cyclohexyl [1,1'-biphenyl]-3-ylcarbamate;

"(x) URB754 (also known as 6-methyl-2-[(4-methylphenyl)amino] -4H-3,1-benzoxazin-4-one); and

"(xii) URB937 (also known as 3'-carbamoyl-6-hydroxy-[1,1'-biphenyl]-3-yl Cyclohexylcarbamate).".

(4) A new paragraph (7) is added to read as follows:

"(7) Synthetic opioids, which includes, unless specifically exempted, unless listed in another schedule, or unless approved by the Food and Drug Administration as a drug, any material, mixture, preparation, any compound structurally derived from, or that contains any quantity of the following synthetic substances, its salts, isomers, homologues, analogues and salts of isomers, homologues, and analogues, whenever the existence of these salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation:

"(A) Classified Synthetic Opioids:

"(i) Fentanyls: Any compound, other than carbomethoxyfentanyls, containing or structurally derived from N-(1-(2-Phenylethyl)-4-piperidinyl)-N-

phenylpropanamide, whether or not substituted on the methanone group with an alkyl, alkene, halo, haloalkyl, benzyl, halobenzyl, alkenyl, haloalkenyl, cyanoalkyl, hydroxyalkyl, furanyl, or alkoxy, and whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Examples of fentanyls include:

"(I) Fentanyl (also known as N-(1-(2-Phenylethyl)-4-piperidinyl)-N-phenylpropanamide);

"(II) Furanylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide);

"(III) Acetylfentanyl (also known as N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide);

"(IV) Acrylfentanyl (also known as N-Phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]prop-2-enamide);

"(V) Parafluorofentanyl, also known as:

"(aa) 4-fluorofentanyl; or

"(bb) N-(4-fluorophenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide;

"(VI) Butyryl fentanyl also known as:

"(aa) Butyr fentanyl;

"(bb) NIH 10486; or

"(cc) N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide, monohydrochloride; and

"(VII) para-Fluorobutyryl fentanyl, also known:

"(aa) 4-FPF;

"(bb) p-FBF;

"(cc) 4-Fluorobutyryl fentanyl;

"(dd) p-Fluorobutyryl fentanyl; or

"(ee) N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide);

"(ii) Carbomethoxyfentanyls: Any compound containing or structurally derived from 4-((1-oxopropyl)-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester, whether or not substituted on either phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group. Carbomethoxyfentanyls include carfentanil, also known as:

"(I) 4-carbomethoxyfentanyl;

"(II) 4-((1-oxopropyl)-phenylamino)-1-(2-phenylethyl)-4-piperidinecarboxylic acid methyl ester; or

"(III) Carfentanyl;

"(iii) Benzamides: Any compound containing or structurally derived from 3,4-Dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide, whether or not substituted on the phenyl ring with an alkyl, halo, cycloalkyl, or alkoxy group, and whether or not substituted with an alkyl or hydrogen on the nitrogen of the amide, and whether or not substituted on the nitrogen of the amide with an alkyl, cycloalkyl, tertiary amine, or combination thereof. Benzamides include:

"(I) U-47700 (also known as 3,4-dichloro-N-[(1R,2R)-2-(dimethylamino)cyclohexyl]-N-methylbenzamide); and

"(II) AH-7921 (also known as 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide).

"(B) Unclassified Synthetic Opioids:

"(I) W-18 (also known as 4-chloro-N-[(2Z)-1-[2-(4-nitrophenyl)ethyl]piperidin-2-ylidene]benzene-1-sulfonamide).".

(c) Section 208(a)(7) (D.C. Official Code § 48-902.08(a)(7)) is repealed.

Sec. 3. Fiscal impact statement.

The Council adopts the fiscal impact statement of the Chief Financial Officer as the fiscal impact statement required by section 4a of the General Legislative Procedures Act of 1975, approved October 16, 2006 (120 Stat. 2038; D.C. Official Code § 1-301.47a).

Sec. 4. Effective date.

(a) This act shall take effect following approval by the Mayor (or in the event of veto by the Mayor, action by the Council to override the veto), a 30-day period of congressional review as provided in section 602(c)(1) of the District of Columbia Home Rule Act, approved December 24, 1973 (87 Stat. 813; D.C. Official Code § 1-206.02(c)(1)), and publication in the District of Columbia Register.

(b) This act shall expire after 225 days of its having taken effect

_____

Chairman
Council of the District of Columbia

877 _____

878 Mayor

879 District of Columbia

880

GOVERNMENT OF THE DISTRICT OF COLUMBIA
Office of the Attorney General

ATTORNEY GENERAL
KARL A. RACINE

Legal Counsel Division

MEMORANDUM

TO: James Pittman
Deputy Attorney General for Legislative, Intergovernmental, and Community Engagement
Office of the Attorney General

FROM: Janet M. Robins
Deputy Attorney General
Legal Counsel Division

DATE: December 1, 2017

SUBJECT: Legal Sufficiency Review of Draft Emergency, Temporary, and Permanent Synthetics Abatement and Full Enforcement Drug Control Legislation (AE-15-744 G)

This is to Certify that this Office has reviewed the above-referenced draft legislation and found it to be legally sufficient. If you have any questions in this regard, please do not hesitate to call me at 724-5524.

JMR/GPalon

Janet M. Robins